ArticleResearch and practice in thrombosis and haemostasis2023
Mechanisms of cancer-associated thrombosis.
Article in Research and practice in thrombosis and haemostasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Biomarkers of Hypercoagulability and Thromboinflammation in Cervical Cancer-Associated Thrombosis: A Systematic Review with Translational Insights from Breast Cancer.International journal of molecular sciences · 2026Pooled it
- Antithrombotic therapy for secondary stroke prevention in patients with cancer: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- A Mitochondrial-Related Gene Signature for Diagnosis and Immune Microenvironment Modulation in Lung Cancer and Venous Thromboembolism.World journal of oncology · 2026Article
- Article
- Review
- Article
- Integrative Multi-Omics Analysis Identifies Thrombosis-Associated Molecular Features Linked to Germline Susceptibility and Immune Cell Communication in Gastric Cancer.Chemical biology & drug design · 2026Article
- Pulmonary origin and risk assessment of cancer-associated thrombosis.Thrombosis journal · 2026Review
- Risk stratification of in-hospital venous thromboembolism for urological cancers: a multicenter retrospective study.Therapeutic advances in medical oncology · 2026Article
- Histological differences among thrombi in thrombotic diseases.Current opinion in hematology · 2025Review
- Observational
- Tissue factor, factor VIII and IX in microvesicle-induced thrombosis and tumor growth of pancreatic cancer.Thrombosis journal · 2025Article
- Article
- Venous thrombosis and obesity: from clinical needs to therapeutic challenges.Internal and emergency medicine · 2025Review
- Unravelling the role of TET2 in venous thromboembolism: insights into mechanisms and therapeutic implications.Frontiers in cardiovascular medicine · 2025Review
- Perioperative laboratory profiles predict complications after extensive head and neck reconstruction: a proof-of-concept study.Frontiers in oncology · 2025Article
- Using heart rate variability to evaluate the association between the autonomic nervous system and coagulation function in patients with endometrial cancer.Oncology letters · 2024Article
- Unprovoked venous thromboembolism recurrence and arterial embolism revealing lung cancer: a case report.Thrombosis journal · 2024Article
- The regulation of cancer-associated thrombosis by podoplanin.Thrombosis update · 2024Article
- The pathogenesis of cancer-associated thrombosis.International journal of hematology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A State-of-the-Art lecture titled "Mechanisms of cancer-associated thrombosis" was presented at the ISTH Congress in 2022. Patients with cancer have a 4-fold to 9-fold increased risk of venous thromboembolism (VTE) compared with the general population, so-called cancer-associated thrombosis (CAT). Different rates of VTE are observed in different types of cancer, suggesting that there are cancer-type specific mechanisms of CAT. We will discuss 4 pathways of CAT: tissue factor, podoplanin, neutrophil extracellular traps, and plasminogen activator inhibitor-1. In addition, specific gene mutations may increase the rate of CAT in some cancer types. A better understanding of these pathways may lead to the identification of biomarkers that can identify patients at risk for VTE and allow the development of new treatments to prevent CAT. Finally, we summarize relevant new data on this topic presented at the 2022 ISTH Congress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.